Hospital
ST. Joseph Hospital
ST. Joseph Hospital was paid $38.82M by Medicaid between Jan 2018 and Dec 2024, across 424 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 13% of everything it billed.
33Billing provider infoST. JOSEPH HOSPITAL
BANGOR, ME 04401
BANGOR, ME 04401
33aNPI1154321545assigned 07/28/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$38.82M
24GClaims1,209,997
24DCodes billed424
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Maine
Rank by total paid#5 of 33
Median peer was paid$4.34M
This provider vs. median8.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 128,570 | $2.55M | |
| 2019 | 172,149 | $3.80M | |
| 2020 | 149,308 | $4.18M | |
| 2021 | 173,973 | $5.70M | |
| 2022 | 197,551 | $6.75M | |
| 2023 | 200,411 | $7.88M | |
| 2024incomplete | 188,035 | $7.97M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 13% | 106,393 | 86,639 | $5.07M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 35,325 | 32,658 | $4.33M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.4% | 13,704 | 12,323 | $3.64M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.4% | 39,161 | 36,217 | $3.27M |
| Q9992 | Injection, buprenorphine extended-release (sublocade), greater than 100 mg | 7.4% | 1,933 | 1,827 | $2.85M |
| Q9991 | Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg | 5.6% | 1,559 | 1,464 | $2.19M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.5% | 62,234 | 55,524 | $2.13M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.8% | 11,449 | 10,215 | $1.07M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 6,447 | 5,974 | $945K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 2.2% | 2,413 | 2,304 | $864K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 13,094 | 12,048 | $782K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.9% | 1,820 | 1,728 | $742K |
412 more codes
| 99213 | Doctor's office visit, returning patient (routine) | 1.9% | 29,994 | $725K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.9% | 2,843 | $720K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 7,917 | $575K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 5,970 | $553K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 13,403 | $440K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.1% | 7,694 | $432K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 879 | $377K |
| 29581 | <1% | 5,679 | $332K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,508 | $318K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,059 | $312K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,420 | $278K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 876 | $238K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,122 | $228K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 3,678 | $227K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,055 | $211K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,030 | $202K |
| 95811 | <1% | 473 | $195K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 108 | $191K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,555 | $189K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 2,993 | $163K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,675 | $154K |
| 94726 | <1% | 3,935 | $141K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,104 | $132K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,170 | $123K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,922 | $114K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,730 | $111K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 893 | $104K |
| 76830 | Ultrasound, transvaginal | <1% | 1,539 | $100K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 2,408 | $100K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 26 | $96K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 23,060 | $88K |
| 80053 | Comprehensive metabolic panel | <1% | 55,225 | $81K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,842 | $81K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15,389 | $79K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,726 | $76K |
| 71250 | <1% | 1,848 | $74K | |
| 80061 | Lipid panel | <1% | 12,611 | $72K |
| 94060 | <1% | 712 | $71K | |
| 76536 | <1% | 2,361 | $69K | |
| 76642 | <1% | 1,781 | $67K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,435 | $66K |
| 98927 | <1% | 4,155 | $59K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 926 | $59K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,598 | $57K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 56,297 | $54K |
| 72141 | <1% | 440 | $54K | |
| 77066 | Tomosynthesis, mammo | <1% | 766 | $52K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,597 | $50K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 366 | $49K |
| 99205 | Prolong outpt/office vis | <1% | 627 | $49K |
| 71271 | <1% | 1,092 | $48K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 941 | $43K |
| 90837 | Psychotherapy session, about an hour | <1% | 463 | $37K |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 82 | $36K |
| 93971 | <1% | 781 | $34K | |
| 90677 | <1% | 309 | $33K | |
| 93017 | <1% | 1,245 | $32K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 71,258 | $32K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 145 | $31K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,169 | $31K |
| 90686 | <1% | 3,226 | $29K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 12 | $28K |
| 99406 | <1% | 3,062 | $28K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,415 | $28K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,325 | $27K |
| 11719 | <1% | 1,974 | $26K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,985 | $25K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 104 | $25K |
| 82728 | <1% | 5,047 | $24K | |
| 95806 | <1% | 252 | $23K | |
| 72100 | <1% | 1,587 | $22K | |
| 82607 | <1% | 4,219 | $22K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,799 | $21K |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | <1% | 1,080 | $21K |
| 43235 | <1% | 69 | $21K | |
| 97161 | <1% | 944 | $20K | |
| 73221 | <1% | 149 | $18K | |
| 97597 | <1% | 342 | $18K | |
| 76770 | <1% | 379 | $18K | |
| G0400 | Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels | <1% | 76 | $17K |
| 77080 | <1% | 695 | $17K | |
| 99495 | <1% | 432 | $17K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 580 | $16K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 243 | $15K |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | <1% | 18 | $15K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,585 | $15K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,584 | $15K |
| 73564 | <1% | 834 | $13K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 62 | $12K |
| 83550 | <1% | 4,179 | $12K | |
| 90732 | <1% | 330 | $12K | |
| 99443 | <1% | 435 | $12K | |
| 83970 | <1% | 1,455 | $11K | |
| 70486 | <1% | 285 | $11K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,695 | $11K |
| 77065 | Tomosynthesis, mammo | <1% | 254 | $11K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 578 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,876 | $11K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 29 | $10K |
| 84439 | <1% | 3,213 | $10K | |
| 73130 | <1% | 1,361 | $10K | |
| 86803 | <1% | 2,079 | $10K | |
| 94010 | <1% | 2,535 | $10K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,331 | $10K |
| 73630 | <1% | 1,800 | $10K | |
| 86235 | <1% | 482 | $10K | |
| 83540 | <1% | 4,299 | $9K | |
| 20610 | <1% | 98 | $9K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 46 | $9K |
| 73030 | <1% | 1,475 | $9K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 434 | $9K |
| 96367 | <1% | 324 | $9K | |
| 86140 | <1% | 8,611 | $9K | |
| 96415 | <1% | 311 | $9K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 15 | $8K |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 54 | $8K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 500 | $8K |
| 94618 | <1% | 953 | $8K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 489 | $7K |
| 80305 | <1% | 5,286 | $7K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 16 | $7K |
| 96373 | <1% | 45 | $7K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 62 | $7K |
| 93242 | <1% | 314 | $6K | |
| 83880 | <1% | 2,649 | $6K | |
| 73610 | <1% | 948 | $6K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 595 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,405 | $6K |
| 80076 | <1% | 2,733 | $5K | |
| D3221 | <1% | 25 | $5K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 445 | $5K |
| 80050 | General health panel | <1% | 225 | $5K |
| 83735 | <1% | 17,350 | $5K | |
| 94729 | <1% | 4,276 | $5K | |
| 74183 | <1% | 25 | $5K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 327 | $5K |
| 85652 | <1% | 8,126 | $5K | |
| 99442 | <1% | 300 | $5K | |
| 82043 | <1% | 3,094 | $5K | |
| 73110 | <1% | 422 | $5K | |
| 84403 | <1% | 261 | $4K | |
| 73502 | <1% | 941 | $4K | |
| 93270 | <1% | 313 | $4K | |
| 97162 | <1% | 200 | $4K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 101 | $4K |
| J0248 | Injection, remdesivir, 1 mg | <1% | 134 | $4K |
| 85610 | <1% | 5,842 | $4K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 28 | $3K |
| 70491 | <1% | 27 | $3K | |
| 86200 | <1% | 734 | $3K | |
| D1120 | Dental cleaning, child | <1% | 141 | $3K |
| 98928 | <1% | 364 | $3K | |
| 84153 | <1% | 334 | $3K | |
| 72050 | <1% | 125 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 131 | $3K |
| 82565 | <1% | 2,151 | $3K | |
| 83690 | <1% | 11,469 | $3K | |
| 81001 | <1% | 9,192 | $2K | |
| 77062 | <1% | 98 | $2K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 38 | $2K |
| 85027 | <1% | 2,641 | $2K | |
| 90656 | <1% | 202 | $2K | |
| 90746 | <1% | 42 | $2K | |
| 87070 | <1% | 1,961 | $2K | |
| 95251 | <1% | 129 | $2K | |
| 87641 | <1% | 218 | $2K | |
| 51798 | <1% | 1,037 | $2K | |
| 86225 | <1% | 461 | $2K | |
| 87186 | <1% | 2,439 | $2K | |
| 93225 | <1% | 42 | $2K | |
| 95800 | <1% | 187 | $2K | |
| 86618 | <1% | 377 | $2K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 278 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,473 | $2K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $2K |
| 86038 | <1% | 289 | $2K | |
| 82746 | <1% | 359 | $2K | |
| 00811 | <1% | 311 | $2K | |
| 97803 | <1% | 170 | $2K | |
| 84484 | <1% | 16,375 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,532 | $2K |
| 87522 | Neg quan hep c or qual rna | <1% | 73 | $2K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 14 | $2K |
| 87340 | <1% | 429 | $2K | |
| 90662 | <1% | 868 | $2K | |
| 86039 | <1% | 454 | $1K | |
| 91322 | <1% | 58 | $1K | |
| 86160 | <1% | 213 | $1K | |
| 81025 | <1% | 5,665 | $1K | |
| 73562 | <1% | 387 | $1K | |
| 86706 | <1% | 325 | $1K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 35 | $1K |
| 97116 | <1% | 1,862 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 141 | $1K |
| 82784 | <1% | 386 | $1K | |
| G0378 | Hospital observation service, per hour | <1% | 4,712 | $1K |
| 00731 | <1% | 671 | $1K | |
| G0008 | Administration of influenza virus vaccine | <1% | 2,122 | $1K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 1,687 | $1K |
| 87077 | <1% | 2,609 | $1K | |
| 81003 | <1% | 11,074 | $1K | |
| 86431 | <1% | 628 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 171 | $1K |
| 82962 | <1% | 11,933 | $1K | |
| 87205 | <1% | 2,155 | $1K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 910 | $1K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 189 | $1K |
| 10060 | <1% | 13 | $1K | |
| 99496 | <1% | 14 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,802 | $1K |
| 84100 | <1% | 1,923 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 724 | $964.34 |
| 82550 | <1% | 1,204 | $951.74 | |
| 93244 | <1% | 83 | $887.51 | |
| 87493 | <1% | 99 | $878.41 | |
| 87631 | <1% | 869 | $874.70 | |
| 83516 | <1% | 285 | $850.29 | |
| 82077 | <1% | 3,066 | $846.27 | |
| 93016 | <1% | 75 | $819.04 | |
| 85379 | <1% | 3,253 | $801.34 | |
| 11055 | <1% | 34 | $770.36 | |
| 84703 | <1% | 1,008 | $704.62 | |
| 82570 | <1% | 304 | $703.30 | |
| 64415 | <1% | 29 | $665.26 | |
| 93228 | <1% | 42 | $612.66 | |
| 71101 | <1% | 85 | $593.21 | |
| 87040 | <1% | 3,819 | $585.17 | |
| 83605 | <1% | 7,030 | $580.13 | |
| D1206 | Topical application of fluoride varnish | <1% | 123 | $571.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 19 | $545.99 |
| 99221 | <1% | 15 | $543.30 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,515 | $527.77 |
| 84550 | <1% | 526 | $509.65 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 55 | $497.60 |
| 93018 | <1% | 71 | $495.44 | |
| 86704 | <1% | 156 | $480.59 | |
| 84402 | <1% | 29 | $470.02 | |
| 93272 | <1% | 40 | $468.28 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 993 | $458.54 |
| 76870 | <1% | 14 | $456.20 | |
| 77061 | <1% | 13 | $456.05 | |
| 72202 | <1% | 13 | $437.17 | |
| 86481 | <1% | 16 | $427.35 | |
| 81002 | <1% | 1,892 | $400.94 | |
| 84702 | <1% | 113 | $397.33 | |
| 82805 | <1% | 276 | $388.05 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,898 | $382.63 |
| 90480 | <1% | 55 | $381.72 | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 14 | $378.72 |
| 88342 | <1% | 953 | $369.11 | |
| 87640 | <1% | 217 | $360.70 | |
| 96127 | <1% | 130 | $357.22 | |
| 86900 | <1% | 90 | $326.65 | |
| 97165 | <1% | 15 | $317.14 | |
| 97802 | <1% | 23 | $290.85 | |
| 99223 | Prolong inpt eval add15 m | <1% | 28 | $276.78 |
| 99441 | <1% | 30 | $269.77 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,980 | $263.00 |
| J2704 | Injection, propofol, 10 mg | <1% | 19,721 | $262.21 |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 89 | $259.16 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,192 | $258.60 |
| 84480 | <1% | 42 | $257.36 | |
| 96376 | <1% | 3,080 | $234.45 | |
| 86800 | <1% | 24 | $228.26 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,273 | $207.32 |
| 83993 | <1% | 16 | $196.30 | |
| 85730 | <1% | 265 | $183.83 | |
| 87075 | <1% | 168 | $177.94 | |
| 84156 | <1% | 190 | $169.29 | |
| 73080 | <1% | 44 | $159.12 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,299 | $153.62 |
| 80178 | <1% | 61 | $153.35 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,884 | $152.05 |
| 85018 | <1% | 245 | $150.13 | |
| 74018 | <1% | 44 | $149.27 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,170 | $146.94 |
| 87081 | <1% | 128 | $146.75 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,057 | $143.94 |
| 83721 | <1% | 39 | $140.55 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 328 | $128.81 |
| 87469 | <1% | 14 | $114.62 | |
| 84165 | <1% | 27 | $111.70 | |
| 82310 | <1% | 94 | $111.68 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,115 | $102.20 |
| 80143 | <1% | 259 | $100.00 | |
| 87046 | <1% | 51 | $96.70 | |
| 84481 | <1% | 13 | $93.09 | |
| 81015 | <1% | 111 | $89.10 | |
| 87045 | <1% | 50 | $87.26 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 1,123 | $85.54 |
| 86141 | <1% | 57 | $82.32 | |
| 74022 | <1% | 136 | $72.36 | |
| 86430 | <1% | 41 | $64.66 | |
| 0012A | <1% | 66 | $64.08 | |
| 85014 | <1% | 96 | $58.06 | |
| 88304 | <1% | 296 | $51.54 | |
| 86592 | <1% | 14 | $42.70 | |
| 84460 | <1% | 84 | $31.80 | |
| 84450 | <1% | 84 | $31.08 | |
| 99024 | <1% | 33 | $29.00 | |
| 87427 | <1% | 22 | $28.74 | |
| C9399 | Unclassified drugs or biologicals | <1% | 19 | $28.16 |
| G0407 | Follow-up inpatient consultation, intermediate, physicians typically spend 25 minutes communicating with the patient via telehealth | <1% | 47 | $27.22 |
| 84132 | <1% | 51 | $24.34 | |
| 86666 | <1% | 37 | $24.03 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 743 | $21.93 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 64 | $21.39 |
| 90715 | <1% | 1,835 | $19.01 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,557 | $17.45 |
| 82140 | <1% | 28 | $14.57 | |
| 82150 | <1% | 24 | $14.07 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,111 | $13.17 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,428 | $13.05 |
| 0011A | <1% | 61 | $12.98 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,694 | $12.73 |
| 86753 | <1% | 13 | $11.99 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 325 | $10.03 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,917 | $9.65 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 309 | $6.80 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,528 | $4.02 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,872 | $3.71 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,189 | $2.42 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 715 | $1.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 639 | $0.50 |
| 3017F | 0% | 772 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 684 | $0.00 |
| 94760 | 0% | 250 | $0.00 | |
| 86850 | 0% | 26 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,396 | $0.00 |
| 00813 | 0% | 454 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,430 | $0.00 |
| J3490 | Unclassified drugs | 0% | 2,354 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 1,084 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 602 | $0.00 |
| 1036F | 0% | 1,015 | $0.00 | |
| 1123F | 0% | 855 | $0.00 | |
| A4217 | Sterile water/saline, 500 ml | 0% | 100 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 69 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 102 | $0.00 |
| 3074F | 0% | 679 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 215 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 385 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 235 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 259 | $0.00 |
| A9270 | Non-covered item or service | 0% | 12,190 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 740 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 380 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 398 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 60 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 20 | $0.00 |
| 83615 | 0% | 13 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 140 | $0.00 |
| 86901 | 0% | 105 | $0.00 | |
| G8428 | Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given | 0% | 15 | $0.00 |
| 3044F | 0% | 24 | $0.00 | |
| 12001 | 0% | 53 | $0.00 | |
| 3079F | 0% | 48 | $0.00 | |
| 0064A | 0% | 15 | $0.00 | |
| 01400 | 0% | 42 | $0.00 | |
| 00790 | 0% | 12 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 50 | $0.00 |
| 36416 | 0% | 13 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 27 | $0.00 |
| 12002 | 0% | 12 | $0.00 | |
| 87147 | 0% | 14 | $0.00 | |
| 1126F | 0% | 18 | $0.00 | |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 13 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 2,223 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 679 | $0.00 |
| 76981 | 0% | 14 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 527 | $0.00 |
| 73140 | 0% | 13 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 470 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 842 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 1,542 | $0.00 |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 819 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 1,485 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 163 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 99 | $0.00 |
| 3078F | 0% | 824 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 93 | $0.00 |
| 3023F | 0% | 357 | $0.00 | |
| G8484 | Influenza immunization was not administered, reason not given | 0% | 260 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 538 | $0.00 |
| 80179 | 0% | 203 | $0.00 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | 0% | 64 | $0.00 |
| 83037 | 0% | 18 | $0.00 | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 17 | $0.00 |
| 00812 | 0% | 951 | $0.00 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 174 | $0.00 |
| 1159F | 0% | 23 | $0.00 | |
| 3077F | 0% | 12 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 53 | $0.00 |
| 1090F | 0% | 135 | $0.00 | |
| 76942 | 0% | 13 | $0.00 | |
| 94664 | 0% | 61 | $0.00 | |
| J0735 | Injection, clonidine hydrochloride, 1 mg | 0% | 20 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 20 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 380 | $0.00 |
| 90750 | 0% | 16 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 41 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 118 | $0.00 |
| 1160F | 0% | 23 | $0.00 | |
| 93325 | 0% | 12 | $0.00 | |
| 90734 | 0% | 16 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 84 | $0.00 |
| 4004F | 0% | 42 | $0.00 | |
| 85378 | 0% | 12 | $0.00 | |
| J1598 | Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg | 0% | 25 | $0.00 |
| 00520 | 0% | 17 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 52 | $0.00 |
| 00840 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENDRIX, MICHAEL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Alternative Health Services of ST. Joseph INC. | Bangor, ME | $300K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.